Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Tao, Liang ^a   Peng, Lisheng ^a,b   Berntsson, Ronnie P A ^c,d   Liu, Sai Man ^e   Park, Sunhyun ^a,f   Yu, Feifan ^a   Boone, Christopher ^a   Palan, Shilpa ^e   Beard, Matthew ^e   Chabrier, Pierre Etienne ^g   Stenmark, Pal ^c   Krupp, Johannes ^e,g   Dong, Min ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d UMEÅ UNIVERSITY   (Sweden)

^e IPSEN   (France)

^f Korea Institute of Toxicology   (South Korea)

^g Innovation   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BETA GALACTOSIDASE; BOTULINUM TOXIN B; SYNAPTOTAGMIN II; ACETYLCHOLINE RELEASE INHIBITOR; BOTULINUM TOXIN A; PROTEIN BINDING; RECOMBINANT PROTEIN; SYT2 PROTEIN, HUMAN;

BACTERIUM; MUTATION; PROTEIN; SATURATION; TOXIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BRAIN CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; ENZYME ACTIVITY; NEUROTRANSMISSION; NONHUMAN; POINT MUTATION; RECEPTOR BINDING; ANIMAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATCH CLAMP TECHNIQUE; RAT; SITE DIRECTED MUTAGENESIS; TWO HYBRID SYSTEM;

BACTERIA (MICROORGANISMS);

ACETYLCHOLINE RELEASE INHIBITORS; ANIMALS; BOTULINUM TOXINS, TYPE A; HUMANS; MUTAGENESIS, SITE-DIRECTED; NEURONS; PATCH-CLAMP TECHNIQUES; PROTEIN BINDING; RATS; RECOMBINANT PROTEINS; SYNAPTOTAGMIN II; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 85021734647     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00064-y     Document Type: Article

References (54)

1. Schiavo, G., Matteoli, M. & Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766 (2000).
2. Montal, M. Botulinum neurotoxin: A marvel of protein design. Annu. Rev. Biochem. 79, 591-617 (2010).
3. Binz, T. & Rummel, A. Cell entry strategy of clostridial neurotoxins. J. Neurochem. 109, 1584-1595 (2009).
4. Jahn, R. & Scheller, R. H. SNAREs-engines for membrane fusion. Nat. Rev. Mol. Cell Biol. 7, 631-643 (2006).
5. Sutton, R. B., Fasshauer, D., Jahn, R. & Brunger, A. T. Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature 395, 347-353 (1998).
6. Sudhof, T. C. & Rothman, J. E. Membrane fusion: grappling with SNARE and SM proteins. Science 323, 474-477 (2009).
7. Johnson, E. A. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53, 551-575 (1999).
8. Aoki, K. R. Botulinum toxin: A successful therapeutic protein. Curr. Med. Chem. 11, 3085-3092 (2004).
9. Montecucco, C. & Molgo, J. Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 5, 274-279 (2005).
10. Dolly, J. O., Lawrence, G. W., Meng, J. & Wang, J. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 9, 326-335 (2009).
11. Lange, O. et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin. Neuropharmacol. 32, 213-218 (2009).
12. Comella, C. L. et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65, 1423-1429 (2005).
13. Dong, M., Tepp, W. H., Liu, H., Johnson, E. A. & Chapman, E. R. Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell Biol. 179, 1511-1522 (2007).
14. Peng, L., Tepp, W. H., Johnson, E. A. & Dong, M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7, e1002008 (2011).
15. Dong, M. et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162, 1293-1303 (2003).
16. Nishiki, T. et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269, 10498-10503 (1994).
17. Rummel, A., Karnath, T., Henke, T., Bigalke, H. & Binz, T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 279, 30865-30870 (2004).
18. Peng, L. et al. Botulinum neurotoxin D-C uses synaptotagmin I/II as receptors and human synaptotagmin II is not an effective receptor for type B, D-C, and G toxins. J. Cell Sci. 125, 3233-3242 (2012).
19. Jin, R., Rummel, A., Binz, T. & Brunger, A. T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095 (2006).
20. Chai, Q. et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-1100 (2006).
21. Benoit, R. M. et al. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature 505, 108-111 (2014).
22. Dong, M. et al. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 19, 5226-5237 (2008).
23. Dong, M. et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596 (2006).
24. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. & Binz, T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011-2014 (2006).
25. Rummel, A. et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 110, 1942-1954 (2009).
26. Fu, Z., Chen, C., Barbieri, J. T., Kim, J. J. & Baldwin, M. R. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48, 5631-5641 (2009).
27. Montecucco, C. How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem. Sci. 11, 314-317 (1986).
28. Peng, L. et al. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J. Cell Sci. 125, 3233-3242 (2012).
29. Strotmeier, J., Willjes, G., Binz, T. & Rummel, A. Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett. 586, 310-313 (2012).
30. Nishiki, T. et al. The high-Affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378, 253-257 (1996).
31. Pang, Z. P. et al. Synaptotagmin-2 is essential for survival and contributes to Ca2+triggering of neurotransmitter release in central and neuromuscular synapses. J. Neurosci. 26, 13493-13504 (2006).
32. Brin, M. F. et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53, 1431-1438 (1999).
33. Pappert, E. J. & Germanson, T. Botulinum toxin type B vs.Type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov. Disord. 23, 510-517 (2008).
34. Rystedt, A., Karlqvist, M., Bertilsson, M., Naver, H. & Swartling, C. Effect of botulinum toxin concentration on reduction in sweating: A randomized, double-blind study. Acta Derm. Venereol. 93, 674-678 (2013).
35. Bentivoglio, A. R., Del Grande, A., Petracca, M., Ialongo, T. & Ricciardi, L. Clinical differences between botulinum neurotoxin type A and B. Toxicon 107, 77-84 (2015).
36. Takamori, S. et al. Molecular anatomy of a trafficking organelle. Cell 127, 831-846 (2006).
37. Wilhelm, B. G. et al. Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344, 1023-1028 (2014).
38. Berntsson, R. P., Peng, L., Dong, M. & Stenmark, P. Structure of dual receptor binding to botulinum neurotoxin B. Nat. Commun. 4, 2058 (2013).
39. Karimova, G., Pidoux, J., Ullmann, A. & Ladant, D. A bacterial two-hybrid system based on a reconstituted signal transduction pathway. Proc. Natl Acad. Sci. USA 95, 5752-5756 (1998).
40. Hill, K. K., Xie, G., Foley, B. T. & Smith, T. J. Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon 107, 2-8 (2015).
41. Rummel, A. et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl Acad. Sci. USA 104, 359-364 (2007).
42. Berntsson, R. P., Peng, L., Svensson, L. M., Dong, M. & Stenmark, P. Crystal structures of botulinum neurotoxin DC in complex with its protein receptors synaptotagmin I and II. Structure 21, 1602-1611 (2013).
43. Peng, L. et al. Widespread sequence variations in VAMP1 across vertebrates suggest a potential selective pressure from botulinum neurotoxins. PLoS Pathog. 10, e1004177 (2014).
44. Yamasaki, S. et al. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem. 269, 12764-12772 (1994).
45. Eleopra, R. et al. Botulinum neurotoxin serotype D is poorly effective in humans: An in vivo electrophysiological study. Clin. Neurophysiol. 124, 999-1004 (2013).
46. Pirazzini, M. et al. Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett. 587, 3831-3836 (2013).
47. Sikorra, S. et al. Identification and characterization of botulinum neurotoxin A substrate binding pockets and their re-engineering for human SNAP-23. J. Mol. Biol. 428, 372-384 (2016).
48. Chen, S. & Barbieri, J. T. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl Acad. Sci. USA 106, 9180-9184 (2009).
49. Guo, J., Pan, X., Zhao, Y. & Chen, S. Engineering Clostridia neurotoxins with elevated catalytic activity. Toxicon 74, 158-166 (2013).
50. Masuyer, G., Chaddock, J. A., Foster, K. A. & Acharya, K. R. Engineered botulinum neurotoxins as new therapeutics. Annu. Rev. Pharmacol. Toxicol. 54, 27-51 (2014).
51. Wang, J. et al. Longer-Acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B. Biochem. J. 444, 59-67 (2012).
52. Meng, J. et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J. Neurosci. 29, 4981-4992 (2009).
53. Wang, J. et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J. Biol. Chem. 283, 16993-17002 (2008).
54. Tao, L. & Biswas, I. ClpL is required for folding of CtsR in Streptococcus mutans. J. Bacteriol. 195, 576-584 (2013)